Tweetovi

Blokirali ste korisnika/cu @Atelfo

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Atelfo

  1. proslijedio/la je Tweet
    29. sij

    Novartis' summary slide on Zolgensma launch — treated 100 patients just in Q4?

    Poništi
  2. proslijedio/la je Tweet

    Best list yet of all the genome editing trials in humans (n=37) so far.

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    15. sij

    This is probably the most interesting stat in 2020 E&Y Firepower Report and explains the lack of M&A at "69% of surveyed dealmakers say the valuation gap between buyers and sellers is the largest its been since 2008"

    Poništi
  4. proslijedio/la je Tweet
    10. sij

    I missed this paper, "A Structured Approach to Strategic Decisions," by Danny Kahneman, @dan_lavallo and in . Good stuff:

    Poništi
  5. proslijedio/la je Tweet
    9. sij

    Target Protein Degradation commanding a lot of attention : collab w/ : $55M u/f , $2.5B in biobucks after, 5 targets, DELs + E3 proteins. Options to co-dev/co-promote. Nice summary by on previous deals in the space:

    Poništi
  6. proslijedio/la je Tweet
    8. sij

    The scientific foundation for our milasen work was Spinraza, birthed by Adrian Krainer & Frank Bennett. Just 1 of the reasons I’m grateful to & for this launch, supporting more individualized txs for ultrarare disease.

    Poništi
  7. proslijedio/la je Tweet
    6. sij
    Poništi
  8. proslijedio/la je Tweet
    30. pro 2019.

    Time to start planning for 2020? Some events through mid 2020, courtesy of Jefferies to keep an eye on: First, companies in their coverage >$1B mcap

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    29. pro 2019.

    Looking back in 2019 & Really some impressive deals made - if 2020 anything like 2019 we should be very happy Whats interesting no & course no on the list

    Poništi
  10. proslijedio/la je Tweet
    29. pro 2019.

    Some complain that the FDA is too hard on the pharmaceutical industry. It's hard for me to 😭 too much for them. Consider these trends over time: 1- user fees ⬆ 2- warning letters ⬇ 3- % of drug applications approved ⬆

    Poništi
  11. proslijedio/la je Tweet
    29. pro 2019.

    How we know what not to think The total number of possibilities is too large. Authors propose we have a cache of unconscious preferences coded to be of higher value or probability which are then actively selected from.

    Poništi
  12. proslijedio/la je Tweet
    Poništi
  13. proslijedio/la je Tweet
    2. pro 2019.

    Updated analysis of recent biotech IPOs that were taken out. Premiums are 118% higher in 19' compared to next highest year. As mentioned,big pharma will need to acquire growth given patent cliffs & outsourcing of early R&D to smaller Cos. $91B of M&A has gone to recent IPOs

    Poništi
  14. proslijedio/la je Tweet
    29. stu 2019.

    Interesting point: "As a simple rule of thumb...about 50% of the accuracy improvements...going from the regulars to the super[forecaster]s can be attributed to noise reduction. The remaining 25% is information improvement...and...25% [is] bias reduction."

    Poništi
  15. proslijedio/la je Tweet
    19. stu 2019.
    Poništi
  16. proslijedio/la je Tweet

    NEW RESEARCH provides safety, efficacy, and tolerability data for adjunctive cenobamate for patients with uncontrolled focal seizures. Expert commentary from Stephan Arnold suggests that cenobamate could offer new hope for treatment-resistant epilepsy

    Poništi
  17. proslijedio/la je Tweet

    **GIVEAWAY** The new TV adaption of starts tonight on the ! To celebrate, we’re giving you a chance to win a copy of our set of His Dark Materials SIGNED by Philip Pullman and Peter Bailey. RT to enter. Competition ends on 5 November. Best of luck!

    Poništi
  18. proslijedio/la je Tweet
    22. lis 2019.

    Okay, here are my prime editing takes. I'm mostly going to try to be a voice of reason here. Not because I'm hyper critical of the paper but because it's necessary. This field is full of mega hype and cool tech, but cool doesn't get us anywhere unless it works as advertised.

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    10. lis 2019.

    The amazing Mila story of N-of-1 trial for saving a 6yo girl w ’s Disease using a personalized antisense oligonucleotide now in NEJM! Editorial on Individualized Therapies by FDA's Janet Woodcock and Peter Marks

    Poništi
  20. proslijedio/la je Tweet
    4. lis 2019.
    Odgovor korisniku/ci

    Here’s a great deck to help understand what makes Costco so unique. This is why is so unlikely that it may be disrupted anytime soon.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·